Related Experiment Video
Updated: May 9, 2026
11:07
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic
Charlotte Primard1, Johanna Poecheim, Simon Heuking
1School of Pharmaceutical Sciences, University of Geneva, University of Lausanne , 1211 Geneva, Switzerland.
Molecular Pharmaceutics
|July 23, 2013
Summary
New nanoparticles deliver antigens and immune-stimulating signals for effective vaccine development. Nasal administration induced strong systemic and mucosal immunity, with localized adjuvant effects enhancing safety.
Area of Science:
- Biomaterials Science
- Immunology
- Vaccine Delivery Systems
Background:
- Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are effective drug delivery vehicles.
- Toll-Like Receptor-7 (TLR-7) agonists can enhance immune responses.
- Muco-adhesive coatings improve mucosal delivery.
Purpose of the Study:
- To develop and evaluate novel PLGA nanoparticles for antigen and TLR-7 agonist delivery.
- To assess the systemic and mucosal immune responses induced by these nanoparticles.
- To investigate the adjuvant effect of TLR-7 agonist (imiquimod) on immune response polarization.
Main Methods:
- PLGA nanoparticles were formulated with encapsulated antigen and TLR-7 agonist.
- A muco-adhesive chitosan-derivate coating was applied.
- Mice were immunized via subcutaneous or nasal routes.
- Systemic and mucosal immune responses were analyzed.
Main Results:
- Intranasal immunization elicited systemic immune responses comparable to subcutaneous injection.
- Mucosal immunization successfully induced immune responses at local and distal mucosal sites.
- The TLR-7 agonist (imiquimod) demonstrated a localized adjuvant effect.
- Localized adjuvant effect suggests potential for increased vaccine safety.
Conclusions:
- PLGA nanoparticles coated with chitosan derivatives are promising for vaccine delivery.
- Nasal administration is effective for inducing both systemic and mucosal immunity.
- Localized adjuvant effects of TLR-7 agonists may enhance vaccine safety profiles.
